Auro Laboratories [AUROLAB] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Auro Laboratories
BSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Auro Laboratories wins in 6 metrics, Divi's Laboratories wins in 12 metrics, with 0 ties. Divi's Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Auro Laboratories | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 145.29 | 67.57 | Divi's Laboratories |
| Price-to-Book Ratio | 3.32 | 10.40 | Auro Laboratories |
| Debt-to-Equity Ratio | 104.76 | 0.03 | Divi's Laboratories |
| PEG Ratio | -1.27 | 2.55 | Auro Laboratories |
| EV/EBITDA | 88.13 | 49.66 | Divi's Laboratories |
| Profit Margin (TTM) | 5.96% | 23.89% | Divi's Laboratories |
| Operating Margin (TTM) | -8.69% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | N/A | 25.60% | N/A |
| Return on Equity | 4.28% | 14.64% | Divi's Laboratories |
| Return on Assets (TTM) | 1.86% | 12.94% | Divi's Laboratories |
| Free Cash Flow (TTM) | $-180.54M | $2.15B | Divi's Laboratories |
| Dividend Yield | N/A | 0.91% | N/A |
| 1-Year Return | 2.63% | -5.14% | Auro Laboratories |
| Price-to-Sales Ratio (TTM) | 8.64 | 16.13 | Auro Laboratories |
| Enterprise Value | $1.86B | $1,522.01B | Divi's Laboratories |
| EV/Revenue Ratio | 11.30 | 15.77 | Auro Laboratories |
| Gross Profit Margin (TTM) | 67.54% | 60.33% | Auro Laboratories |
| Revenue per Share (TTM) | $26 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | $1.57 | $86.82 | Divi's Laboratories |
| Beta (Stock Volatility) | 0.20 | 0.18 | Divi's Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Auro Laboratories vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Auro Laboratories | -3.33% | -7.33% | -4.38% | -13.53% | -10.49% | -16.18% |
| Divi's Laboratories | -0.67% | 2.26% | -3.33% | -15.42% | 10.79% | -4.06% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Auro Laboratories | 2.63% | 189.75% | 185.44% | 1,208.61% | 4,390.84% | 3,637.29% |
| Divi's Laboratories | -5.14% | 63.08% | 80.80% | 444.71% | 1,530.25% | 8,023.95% |
News Based Sentiment: Auro Laboratories vs Divi's Laboratories
Auro Laboratories
News based Sentiment: NEGATIVE
September proved to be a difficult month for Auro Laboratories, with a significant drop in share price and continued revenue declines overshadowing the long-term optimistic projections. The company's financial struggles are evident, making it a high-risk investment, and the upcoming trading window closure suggests potential significant developments are on the horizon.
Divi's Laboratories
News based Sentiment: MIXED
Divi's Laboratories reported strong Q3 results, but also faces mixed analyst opinions, recent underperformance, and a shift in technical trends. The company is also taking on new debt, indicating a strategic change. These factors create a complex investment narrative.
Performance & Financial Health Analysis: Auro Laboratories vs Divi's Laboratories
| Metric | AUROLAB | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.50B | ₹1.61T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 4,177 | 455,187 |
| 90 Day Avg. Volume | 6,853 | 395,686 |
| Last Close | ₹220.50 | ₹5,826.50 |
| 52 Week Range | ₹170.00 - ₹303.00 | ₹4,955.00 - ₹7,071.50 |
| % from 52W High | -27.23% | -17.61% |
| All-Time High | ₹307.20 (May 06, 2024) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -28.22% | -17.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.52% | 0.14% |
| Quarterly Earnings Growth | -0.52% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.24% |
| Operating Margin (TTM) | -0.09% | 0.26% |
| Return on Equity (TTM) | 0.04% | 0.15% |
| Debt to Equity (MRQ) | 104.76 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹68.67 | ₹563.87 |
| Cash per Share (MRQ) | ₹1.02 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹74.16M | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹18.39M | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.91% |
| Last 12-Month Dividend | N/A | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Auro Laboratories vs Divi's Laboratories
| Metric | AUROLAB | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 145.29 | 67.57 |
| Forward P/E | N/A | 104.19 |
| PEG Ratio | -1.27 | 2.55 |
| Price to Sales (TTM) | 8.64 | 16.13 |
| Price to Book (MRQ) | 3.32 | 10.40 |
| Market Capitalization | ||
| Market Capitalization | ₹1.50B | ₹1.61T |
| Enterprise Value | ₹1.86B | ₹1.52T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 11.30 | 15.77 |
| Enterprise to EBITDA | 88.13 | 49.66 |
| Risk & Other Metrics | ||
| Beta | 0.20 | 0.18 |
| Book Value per Share (MRQ) | ₹68.67 | ₹563.87 |
Financial Statements Comparison: Auro Laboratories vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AUROLAB | DIVISLAB |
|---|---|---|
| Revenue/Sales | ₹27.74M | ₹24.10B |
| Cost of Goods Sold | ₹9.01M | ₹9.56B |
| Gross Profit | ₹18.74M | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-2.41M | ₹6.17B |
| EBITDA | ₹4.49M | ₹8.48B |
| Pre-Tax Income | ₹-1.06M | ₹7.33B |
| Income Tax | ₹0 | ₹1.88B |
| Net Income (Profit) | ₹-1.06M | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AUROLAB | DIVISLAB |
|---|---|---|
| Cash & Equivalents | ₹3,000 | ₹4.15B |
| Total Current Assets | ₹215.14M | ₹100.81B |
| Total Current Liabilities | ₹216.42M | ₹14.52B |
| Long-Term Debt | ₹330.85M | ₹20.00M |
| Total Shareholders Equity | ₹429.68M | ₹149.69B |
| Retained Earnings | ₹359.52M | ₹134.00B |
| Property, Plant & Equipment | ₹16.55M | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AUROLAB | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AUROLAB | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 4,177 | 455,187 |
| Average Daily Volume (90 Day) | 6,853 | 395,686 |
| Shares Outstanding | 6.23M | 265.47M |
| Float Shares | 2.50M | 120.77M |
| % Held by Insiders | 0.60% | 0.52% |
| % Held by Institutions | 0.00% | 0.29% |
Dividend Analysis & Yield Comparison: Auro Laboratories vs Divi's Laboratories
| Metric | AUROLAB | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹60.00 |
| Last 12-Month Dividend Yield | N/A | 0.91% |
| 3-Year Avg Annual Dividend | N/A | ₹50.00 |
| 3-Year Avg Dividend Yield | N/A | 0.70% |
| 3-Year Total Dividends | N/A | ₹150.00 |
| Ex-Dividend Date | N/A | Jul 25, 2025 |